Browsing Bergen Open Research Archive by Author "Sorbye, Halfdan"
Now showing items 1-9 of 9
-
Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients
Aasebø, Kristine; Dragomir, Anca; Sundström, Magnus; Mezheyeuski, Artur; Edqvist, Per-Henrik; Eide, Geir Egil; Pontén, Fredrik; Pfeiffer, Per; Glimelius, Bengt; Sorbye, Halfdan (Peer reviewed; Journal article, 2019-05-09) -
A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer
Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge (Peer reviewed; Journal article, 2016-12)Background: The primary aim of our study was to evaluate the safety and potential toxicity of gemcitabine combined with microbubbles under sonication in inoperable pancreatic cancer patients. The secondary aim was to ... -
Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
Løes, Inger Marie; Immervoll, Heike; Sorbye, Halfdan; Angelsen, Jon-Helge; Horn, Arild; Knappskog, Stian; Lønning, Per Eystein (Peer reviewed; Journal article, 2016-04)We determined prognostic impact of KRAS, BRAF, PIK3CA and TP53 mutation status and mutation heterogeneity among 164 colorectal cancer (CRC) patients undergoing liver resections for metastatic disease. Mutation status was ... -
Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis
Nunes, Luís; Aasebø, Kristine; Mathot, Lucy; Ljungström, Viktor; Edqvist, Per-Henrik; Sundström, Magnus; Dragomir, Anca; Pfeiffer, Per; Ameur, Adam; Pontén, Fredrik; Mezheyeuski, Artur; Sorbye, Halfdan; Sjöblom, Tobias; Glimelius, Bengt (Journal article; Peer reviewed, 2020-01-10)Background: We have reported that BRAF V600E mutations and microsatellite instability-high (MSI-H) are more prevalent in a population-based cohort of metastatic colorectal cancer (mCRC) patients than has been reported from ... -
Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial
Labori, Knut Jørgen; Lassen, Kristoffer; Hoem, Dag; Grønbech, Jon Erik; Søreide, Jon Arne; Mortensen, Kim Erlend; Smaaland, Rune; Sorbye, Halfdan; Verbeke, Caroline Sophie; Dueland, Svein (Peer reviewed; Journal article, 2017-08-25)Background: Pancreatic cancer is the fourth leading cause of cancer-related death. While surgical resection remains the foundation for potentially curative treatment, survival benefit is achieved with adjuvant oncological ... -
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: A multicenter cohort study
Carlsen, Esben Andreas; Fazio, Nicola; Granberg, Dan; Grozinsky-Glasberg, Simona; Ahmadzadehfar, Hojjat; Grana, Chiara Maria; Zandee, Wouter T.; Cwikla, Jaroslaw; Walter, Martin A.; Oturai, Peter Sandor; Rinke, Anja; Weaver, Andrew; Frilling, Andrea; Gritti, Sara; Arveschoug, Anne Kirstine; Meirovitz, Amichay; Knigge, Ulrich; Sorbye, Halfdan (Peer reviewed; Journal article, 2019)Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine tumors grade 1–2 (G1–G2). However, its possible benefit in high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms ... -
Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases
Angelsen, Jon-Helge; Viste, Asgaut; Løes, Inger Marie; Eide, Geir Egil; Hoem, Dag; Sorbye, Halfdan; Horn, Arild (Peer reviewed; Journal article, 2015-12-03)Background: Despite progress in resection for colorectal liver metastases (CLM), the majority of patients experience recurrence. We aimed to evaluate factors influencing time to recurrence (TTR), treatment and post-recurrence ... -
Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach
Joranger, Pål; Nesbakken, Arild; Sorbye, Halfdan; Hoff, Geir; Oshaug, Arne; Aas, Eline (Peer reviewed; Journal article, 2020)New and emerging advances in colorectal cancer (CRC) treatment combined with limited healthcare resources highlight the need for detailed decision-analytic models to evaluate costs, survival and quality-adjusted life years. ... -
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
Hamfjord, Julian; Guren, Tormod Kyrre; Dajani, Olav; Johansen, Julia Sidenius; Glimelius, Bengt; Sorbye, Halfdan; Pfeiffer, Per; Lingjærde, Ole Christian; Tveit, Magne Kjell; Kure, Elin Wenche Hegland; Pallisgaard, Niels; Spindler, Karen-Lise Garm (Peer reviewed; Journal article, 2019-05-02)Background: Metastatic colorectal cancer (mCRC) is a heterogeneous disease where prognosis is dependent both on tumor biology and host factors. Total circulating cell-free DNA (cfDNA) has shown to harbor prognostic information ...